The names are often used interchangeably. Understanding the difference—and the limits of what we know—is a better starting point for any decision about care.
A plant preparation and an isolated compound are not the same product. Their composition, effects, and risks cannot be assumed to be equivalent.
Tabernanthe iboga is a shrub native to Central Africa. Its root bark contains several naturally occurring alkaloids, including ibogaine.
Ibogaine is one of iboga’s psychoactive alkaloids. It has been studied for possible effects on substance dependence and withdrawal.
A product label alone cannot establish identity, purity, strength, or suitability for an individual.
Iboga has longstanding ceremonial and spiritual roles in some Central African communities, including within Bwiti traditions in Gabon and neighbouring areas. Practices and meanings vary between communities; they are not a single, uniform tradition.
Clinical interest in ibogaine is a different context. Extracting a compound does not reproduce the relationships, knowledge, or responsibilities that surround traditional use.
Respect for cultural origins and careful medical assessment belong in the same conversation. Traditional use is not evidence that a treatment is safe for everyone.
Research interest is real. So are the gaps. A powerful personal experience, short-term symptom change, and lasting clinical benefit are different outcomes.
Small studies and observational reports describe reductions in opioid withdrawal symptoms or craving for some participants. Research has also explored other substance-use and mental health outcomes.
Many studies have small samples, limited comparison groups, or incomplete follow-up. These limitations make it difficult to determine who benefits, how long changes last, and how much is attributable to ibogaine rather than other care.
Serious adverse events, including deaths, have been reported. Ibogaine can prolong the heart’s QT interval and trigger dangerous arrhythmias. Medication interactions and individual health factors can increase risk.
Ibogaine should not be presented as a guaranteed cure or a substitute for continuing care. Discuss established treatment options, individual risks, and follow-up support with a qualified clinician.
Read the research critically: find ibogaine systematic reviews on PubMed. Look at study design, adverse events, and follow-up—not only the headline result.
Ibogaine can produce prolonged changes in perception, dream-like imagery, and intense emotional experiences. People’s experiences differ. These effects do not establish therapeutic benefit, and the physical risks—including cardiac effects—need separate medical consideration.
No. Plant preparations contain active compounds and can have unpredictable concentrations. They can also cause serious adverse effects. Neither a traditional origin nor a “natural” label makes a preparation medically safe.
No single experience guarantees sustained recovery. Follow-up care, mental health support, and evidence-based addiction treatment remain important. Reduced opioid tolerance after abstinence can increase overdose risk if opioid use resumes. Discuss an overdose prevention plan and access to naloxone with your clinician, and explore aftercare planning.
Ibogaine is classified as a prescription medicine in New Zealand. Prescription status is not the same as approval of a particular product or evidence that a treatment is suitable for you. Ask a qualified prescriber or pharmacist about current requirements, product status, and lawful access. A provider’s willingness to offer treatment does not establish its safety.
Start with a qualified healthcare professional who knows your medical history, medications, and substance use. Discuss safer, established alternatives as well as your reasons for considering ibogaine. Use our preparation guide to organise questions about assessment, monitoring, emergency arrangements, and follow-up care.
Explore the Treatment Companion App alongside these guides and conversations with your care team.
This guide complements the ibogaine information at ibogaine.nz.
Continue at ibogaine.nz